News & Media

News & Media

Press releases

May 7, 2019
Kyn Therapeutics Strengthens Leadership Team with Key Appointments

February 4, 2019
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer

January 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

December 19, 2018
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

In the news

Xconomy
Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups

Endpoints News
Celgene inks first deals since Bristol-Myers announced $74B buyout — bets $80M on immunometabolism

Boston Business Journal
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

Bloomberg
Bloomberg Baystate Business: Biogen, Budget and ESG

view all Tweets

Twitter

@KynTherapeutics
#TBT to some of our favorite memories from the past few months. We're excited to welcome lots of new members to our… http://dZaFJ8mt4h

@KynTherapeutics
We're currently conducting two Phase 1b/2 studies of our lead program, ARY-007, an antagonist of the EP4 receptor.… http://S3lykAl6sM

@KynTherapeutics
May is National Cancer Research Month. We're grateful for our dedicated team of researchers at Kyn, whose diverse b… http://kcaYf3deOD

@KynTherapeutics
Here's Kyn scientist @MartaSMbio representing our team at the conference in NY! http://yFhY7kgoUY

Corporate fact sheet

download now

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
50 Northern Avenue
7th Floor
Boston, MA 02210

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn